The Column Group
Overview
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry. TCG takes a novel approach to venture capital funding with an edge-to-edge investment model primarily focused on company formation but with the financial wherewithal for long-term private and public capital support. This model exists within an ecosystem of funds, each with a clear strategy and focus, and all with a mandate of maximizing success through collaborative action. TCG Platform funds, TCG Opportunity funds, TCG Labs-Soleil and TCG Crossover (TCGX) wield complementary approaches for deploying capital and work together to propel technology platforms, single assets and later-stage programs forward from inception through exit.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Tortugas Neuroscience | Apr 2026 | Seed | Lead |
| Atavistik | Mar 2026 | Series B | Co-investor |
| Atavistik | Dec 2025 | Series B | Lead |
| Tr1X | Oct 2025 | VC Round | Co-investor |
| Nilo Therapeutics | Oct 2025 | Series A | Lead |
Key People
Peter Svennilson
Managing Partner And Founder
David Goeddel
Managing Partner
Tim Kutzkey
Managing Partner
Arnav Mehta
Venture Partner
Brian Wong
Venture Partner
John Josey
Venture Partner
Carla Daniel
Partner Chief People Officer
Jeff Goater
Partner
Larry Lasky
Partner
Sarah Hymowitz
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.